ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
TipRanks on MSN
ResMed Inc. Reports Changes in Beneficial Ownership
The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ). ResMed Inc. has reported ...
Zacks Investment Research on MSN
Do Options Traders Know Something About ResMed Stock We Don't?
Investors in ResMed Inc. RMD need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 16, 2026 $155.00 Call had some of the highest implied ...
Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year ...
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated ...
In contrast to all that, many investors prefer to focus on companies like ResMed (NYSE:RMD), which has not only revenues, but also profits. Even if this company is fairly valued by the market, ...
The market awaits ResMed's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...
Expands ResMed’s out-of-hospital software portfolio into skilled nursing and senior living verticals Enhances ResMed’s ability to improve patient transitions of care and provider efficiencies Purchase ...
For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of ...
Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A replay of the earnings webcast will be accessible on ...
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4 th to discuss the Company’s recent acquisitions, existing joint ventures ...
With the pandemic-induced chip shortage still ballooning around the world, ResMed has been forced to deflate its expectations for what it hoped to reap in the vacuum caused by Philips’ major ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback